BDX
Becton Dickinson and Co
$
172.820
- Overview
- Forecast
- Valuation
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
174.000
Open
171.330
VWAP
171.84
Vol
2.94M
Mkt Cap
47.93B
Low
170.730
Amount
505.66M
EV/EBITDA(TTM)
13.01
Total Shares
289.01M
EV
66.51B
EV/OCF(TTM)
19.96
P/S(TTM)
2.32
Becton, Dickinson and Company is a global medical technology company. The Company is engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, and others. The Company's BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a wide range of settings. The BD Medical segment consists of various business units, including medication delivery solutions, medication management solutions, and pharmaceutical systems. The Company's BD Life Sciences segment provides products for the collection and transport of diagnostics specimens, and instruments and reagent systems to detect a broad range of infectious diseases, healthcare-associated infections and cancers. The Company's BD Interventional segment provides vascular, urology, oncology and surgical specialty products.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2026Q1
FY2025Q4
FY2025Q3
5.37B
+4%
3.299
-3.82%
5.89B
+8.3%
3.984
+4.56%
5.50B
+8.77%
3.431
-1.97%
Estimates Revision
The market is revising Downward the revenue expectations for Becton, Dickinson and Company (BDX) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by -23.48%.
Revenue Estimates for FY2025
Revise Downward
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
-1.95%
In Past 3 Month
Stock Price
Go Down
-23.48%
In Past 3 Month
12 Analyst Rating
19.43% Upside
Wall Street analysts forecast BDX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BDX is 206.40 USD with a low forecast of 172.00 USD and a high forecast of 261.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
8 Hold
0 Sell
Moderate Buy
19.43% Upside
Current: 172.820
Low
172.00
Averages
206.40
High
261.00
19.43% Upside
Current: 172.820
Low
172.00
Averages
206.40
High
261.00
Stifel
Rick Wise
Strong Buy
Maintains
$280 → $224
2025-05-02
Reason
Stifel
Rick Wise
Price Target
$280 → $224
2025-05-02
Maintains
Strong Buy
Reason
Stifel analyst Rick Wise lowered the firm's price target on Becton Dickinson to $224 from $280 and keeps a Buy rating on the shares. Q2 performance and FY25 guidance were both "more disappointing and more complicated than anticipated," the analyst tells investors. Both the Q2 underperformance and now-higher China pressures are factors in the firm's revised estimates and price target, the analyst indicated.
Piper Sandler
Jason Bednar
Buy
to
Hold
Downgrades
$260 → $185
2025-05-02
Reason
Piper Sandler
Jason Bednar
Price Target
$260 → $185
2025-05-02
Downgrades
Buy
to
Hold
Reason
Piper Sandler analyst Jason Bednar downgraded Becton Dickinson to Neutral from Overweight with a price target of $185, down from $260. The firm says its "patience has fully worn out" on the company's "checkered execution path" for organic revenue. Piper's confidence has eroded in management's demand forecasting ability. Becton's fiscal Q2 saw nearly every segment revenue line miss expectatoins on an organic growth basis, the analyst tells investors in a research note. Piper "can no longer justifiably defend" that the company's guidance is achievable.
William Blair
Brian Weinstein
Buy
to
Hold
Downgrades
n/a
2025-05-01
Reason
William Blair
Brian Weinstein
Price Target
n/a
2025-05-01
Downgrades
Buy
to
Hold
Reason
Piper Sandler
Jason Bednar
Buy
Maintains
$280 → $260
2025-04-23
Reason
Piper Sandler
Jason Bednar
Price Target
$280 → $260
2025-04-23
Maintains
Buy
Reason
Piper Sandler analyst Jason Bednar lowered the firm's price target on Becton Dickinson to $260 from $280 and keeps an Overweight rating on the shares ahead of quarterly results. The firm notes that policy and broad economic uncertainty has seemingly created opportunities for investors to do value shopping, with Becton Dickinson (BDX) and Sotera Health (SHC) looking best positioned to respond favorably to upcoming reports when considering current sentiment/positioning.
Barclays
Travis Steed
Buy
Maintains
$279 → $261
2025-04-07
Reason
Barclays
Travis Steed
Price Target
$279 → $261
2025-04-07
Maintains
Buy
Reason
Barclays lowered the firm's price target on Becton Dickinson to $261 from $279 and keeps an Overweight rating on the shares. The firm updated its sum-of-the-parts analysis following reports that the company plans to separate its Bioscience and Diagnostics Solutions business. It cites a drop in peer multiples for the target cut.
Barclays
Travis Steed
Buy
Maintains
$278 → $279
2025-02-14
Reason
Barclays
Travis Steed
Price Target
$278 → $279
2025-02-14
Maintains
Buy
Reason
Barclays raised the firm's price target on Becton Dickinson to $279 from $278 and keeps an Overweight rating on the shares. The firm says its updated sum-of-the-parts valuation analysis suggests 19% upside to Becton from current levels, based on an updated model estimates and several changes to assumptions.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Becton Dickinson and Co (BDX.N) is 11.78, compared to its 5-year average forward P/E of 19.71. For a more detailed relative valuation and DCF analysis to assess Becton Dickinson and Co 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
Strongly Undervalued
5Y Average PE
19.71
Current PE
11.78
Overvalued PE
22.13
Undervalued PE
17.30
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
Strongly Undervalued
5Y Average EV/EBITDA
15.49
Current EV/EBITDA
10.32
Overvalued EV/EBITDA
17.17
Undervalued EV/EBITDA
13.82
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Strongly Undervalued
5Y Average PS
3.57
Current PS
2.15
Overvalued PS
3.92
Undervalued PS
3.22
Financials
Annual
Quarterly
FY2025Q2
YoY :
+4.50%
5.27B
Total Revenue
FY2025Q2
YoY :
-23.00%
646.00M
Operating Profit
FY2025Q2
YoY :
-42.64%
308.00M
Net Income after Tax
FY2025Q2
YoY :
-42.16%
1.07
EPS - Diluted
FY2025Q2
YoY :
-90.79%
35.00M
Free Cash Flow
FY2025Q2
YoY :
-6.26%
42.81
Gross Profit Margin - %
FY2025Q2
YoY :
-45.11%
5.84
Net Margin - %
FY2025Q2
YoY :
+16.41%
4.61
ROIC
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
636.4K
USD
3
3-6
Months
3.1M
USD
10
6-9
Months
0.0
USD
0
0-12
Months
71.8K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
350.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
536.0K
Volume
15
6-9
Months
0.0
Volume
0
0-12
Months
803.3K
Volume
24
Bought
0-3
0
0.0
Volume
Months
3-6
9
298.7K
Volume
Months
6-9
0
0.0
Volume
Months
0-12
16
6.2M
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
81.0K
USD
4
3-6
Months
0.0
USD
0
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
636.4K
USD
3
3-6
Months
3.1M
USD
10
6-9
Months
0.0
USD
0
0-12
Months
71.8K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
1
350.4K
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
BDX News & Events
Events Timeline
2025-05-01 (ET)
2025-05-01
06:37:34
Becton Dickinson cuts FY25 adjusted EPS view to $14.06-$14.34 from $14.30-$14.60
2025-05-01
06:34:06
Becton Dickinson reports Q2 adjusted EPS $3.35, consensus $3.28
2025-03-20 (ET)
2025-03-20
06:54:02
Becton Dickinson announces first patient treated in GalaFLEX trial
Sign Up For More Events
Sign Up For More Events
News
9.5
13:00 PMNewsfilterPinnedBD to Announce Financial Results for its Third Quarter of Fiscal 2025
9.0
05-06BenzingaFDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight
2.0
05-04BenzingaBlock, Becton Dickinson And Pilgrim's Pride Are Among Top 10 Large-Cap Losers Last Week (Apr 28-May 2): Are The Others In Your Portfolio?
Sign Up For More News
People Also Watch
NAUT
Nautilus Biotechnology Inc
0.748
USD
+6.86%
MTA
Metalla Royalty & Streaming Ltd
2.890
USD
-5.56%
ELDN
Eledon Pharmaceuticals Inc
2.930
USD
+1.38%
ATOM
Atomera Inc
7.080
USD
+9.94%
INGN
Inogen Inc
6.300
USD
+0.96%
CPSS
Consumer Portfolio Services Inc
9.790
USD
+4.71%
AVNW
Aviat Networks Inc
20.960
USD
+1.40%
AENT
Alliance Entertainment Holding Corp
2.530
USD
-0.39%
ATAI
ATAI Life Sciences NV
1.440
USD
+3.60%
EVI
EVI Industries Inc
15.880
USD
+1.86%
FAQ
What is Becton Dickinson and Co (BDX) stock price today?
The current price of BDX is 172.82 USD — it has increased 3.35 % in the last trading day.
What is Becton Dickinson and Co (BDX)'s business?
What is the price predicton of BDX Stock?
What is Becton Dickinson and Co (BDX)'s revenue for the last quarter?
What is Becton Dickinson and Co (BDX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Becton Dickinson and Co (BDX)'s fundamentals?
How many employees does Becton Dickinson and Co (BDX). have?